cck-b

CCK-B Receptor Antagonist 1 is a cholecystokinin B (CCK-B) receptor agonist and has the potential of reducing the secretion of gastric acid.

CCK-B Receptor Antagonist 2 is a potent and orally active antagonist of Gastrin CCK-B (IC50: 0.43 nM). It also inhibits gastrin CCK-A activity (IC50: 1.82 μM).

Proglumide (Binoside) 是一种非肽的、口服具有活性的胆囊收缩素(CCK)-A B 受体拮抗剂。它能够选择性阻断 CCK 在中枢神经系统中的作用。它能够抑制胃分泌，具有保护胃十二指肠粘膜的能力，并表现出抗癫痫和抗氧化活性。

Sincalide (CCK-8) 是一种速效的胆囊收缩素的氨基酸多肽激素类似物，可在胆囊造影术中静脉使用。它的肝胆生理作用是增加胆汁的分泌，使胆囊收缩并使 Oddi 的括约肌松弛，从而使胆汁排入十二指肠。它是一种通过注射促进胆囊收缩并帮助诊断胆囊和胰腺疾病的药物。

BC 197 is a selective CCK-B agonist.

Proglumide hemicalcium is a antagonist of nonpeptide and orally active cholecystokinin (CCK)-A/B receptors, has antiepileptic and antioxidant activities.

L-365260 hemihydrate 是选择性的、具有口服活性的非肽胃泌素和脑胆囊收缩素受体 (CCK-B) 拮抗剂，Kis 值分别为 1.9 nM 和 2.0 nM。L-365260 hemihydrate 以竞争性方式与豚鼠胃泌素和脑 CCK 受体相互作用。

CI-1015 is a CCK-B receptor antagonist with oral activity.

L-365260 是一种可口服且具有选择性和高效性的非肽胃泌素和脑胆囊收缩素受体 (CCK-B) 拮抗剂。L-365260 抑制 CCK-8S 诱导的 [Ca2+]i 增加，可阻断应激引起的内脏超敏反应，可阻断 CCK-4 的抗探索作用，可用于研究神经系统Ojibwa和内分泌疾病。

YM022 is a highly effective and selective gastrin/cholecystokinin (CCK)-B receptor antagonist. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively.

L-740093 is a specific antagonist of CCK-B receptor.

Snf 8815 is an antagonist of cholecystokinin-B (CCK-B).

A-57696 is a cholecystokinin antagonist with selective for cortical CCK-B receptors (IC50 = 25 nM).

L-736380 is a CCK-B receptor antagonist. L-736,380 dose-dependently inhibited gastric acid secretion in anesthetized rats (ID(50), 0.064 mg kg) and ex vivo binding of [(125)I]CCK-8S in BKTO mice brain membranes (ED(50), 1.7 mg kg).

[Leu15]-Gastrin I human (Amino Acid Sequence Glp-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Leu-Asp-Phe-NH2) 基因编码人体内的蛋白质 [Leu15]-胃泌素 I。在人类染色体中，GAST 基因定位于 17q21.2。胃窦中的 G 细胞产生 [Leu15]-胃泌素 I 的前体前胃泌素。前胃泌素经过裂解和加工产生胃泌素，它对整个胃肠道上皮细胞具有营养作用。胃泌素对消化系统的生长至关重要，并刺激壁细胞产生胃酸。胃泌素通过称为胆囊收缩素(CCK) 或 CCK-B 受体 (CCK-BR) 的 G 蛋白偶联受体发挥其功能。胃泌素的释放受到食物的刺激，尤其是蛋白质饮食，并受到非常低的 pH 值的抑制。萎缩性胃炎、幽门螺杆菌感染和长期服用质子泵抑制剂感染可能导致胃泌素过度表达。胃腺癌显示高水平的胃泌素。

Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gastrin (cholecystokinin type B (CCK-B)) receptor antagonists may help to elucidate the physiological role o

DA-3934 has a high affinity for gastrin/CCK-B receptors and high selectivity over CCK-A receptors. DA-3934 and its methyl ester derivative inhibited pentagastrin-induced gastric acid secretion in rats in a dose-dependent manner.

CCK2 (CCK-B) receptor antagonist

Sograzepide (Netazepide) 是一种具有口服活性选择性和高效性的 Gastrin CCK-B 拮抗剂，抑制 Gastrin CCK-A 活性，抑制 1 型胃神经内分泌肿瘤中 Pappalysin 2 的表达，可诱导 1 型胃神经内分泌肿瘤消退。